Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 3
Locations
Korea, Republic of
Study Type
Interventional
Intervention
telmisartan/amlodipine 40/5mg
YH22162 40/5/12.5 mg
telmisartan/amlodipine 80/5mg
YH22162 80/5/25 mg
telmisartan/amlodipine 40/5mg placebo
YH22162 40/5/12.5 mg placebo
telmisartan/amlodipine 80/5mg placebo
YH22162 80/5/25 mg placebo
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- Signed Informed Consent
- Men and women ≥ 19 years of age
Essential hypertensive patients
- If already taking antihypertensive drugs, mean sitting systolic blood pressure (MSSBP) must be 140 mmHg ≤ MSSBP < 200 mmHg
- If not taking any antihypertensive drugs at least 4 weeks, mean sitting systolic blood pressure (MSSBP) must be 160 mmHg ≤ MSSBP < 200 mmHg
Exclusion Criteria:
- Patients with known or suspected secondary hypertension
- Other exclusions applied
Sites / Locations
- Yuhan
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
YH22162
telmisartan/amlodipine
Arm Description
YH22162 40/5/12.5 mg (telmisartan 40/amlodipine 5mg/chlorthalidone 12.5mg) for the first 2 weeks, then force titrated to YH22162(telmisartan 80mg/amlodipine 5mg/chlorthalidone 25mg) for the remaining 6weeks
Twynsta(telmisartan 40/amlodipine 5mg) for the first 2 weeks, then force titrated to Twynsta(telmisartan 80mg/amlodipine 5mg) for the remaining 6weeks
Outcomes
Primary Outcome Measures
Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8
Secondary Outcome Measures
Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 2
Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 4
Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSSBP) at Week 2
Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSSBP) at Week 4
Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSSBP) at Week 8
Patients Achieving Blood Pressure Control at Week 2
Mean sitting blood pressure(MSBP) < 140/90 mmHg
Patients Achieving Blood Pressure Control at Week 4
Mean sitting blood pressure(MSBP) < 140/90 mmHg
Patients Achieving Blood Pressure Control at Week 8
Mean sitting blood pressure(MSBP) < 140/90 mmHg
Reduction From Baseline in Mean Sitting Blood Pressure (MSBP) at Week 2
reduction of MSSBP>= 20 mmHg and reduction of MSSBP>= 10 mmHg
Reduction From Baseline in Mean Sitting Blood Pressure (MSBP) at Week 4
reduction of MSSBP>= 20 mmHg and reduction of MSSBP>= 10 mmHg
Reduction From Baseline in Mean Sitting Blood Pressure (MSBP) at Week 8
reduction of MSSBP>= 20 mmHg and reduction of MSSBP>= 10 mmHg
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02620163
Brief Title
Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment
Official Title
A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Trial to Evaluate the Safety and Efficacy of YH22162 in Subjects With Essential Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment
Study Type
Interventional
2. Study Status
Record Verification Date
March 2019
Overall Recruitment Status
Completed
Study Start Date
December 2015 (Actual)
Primary Completion Date
December 2016 (Actual)
Study Completion Date
December 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yuhan Corporation
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
To evaluate efficacy and safety of YH22162 versus telmisartan / amlodipine treatment in patients with hypertension inappropriately controlled on telmisartan/amlodipine treatment
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
381 (Actual)
8. Arms, Groups, and Interventions
Arm Title
YH22162
Arm Type
Experimental
Arm Description
YH22162 40/5/12.5 mg (telmisartan 40/amlodipine 5mg/chlorthalidone 12.5mg) for the first 2 weeks, then force titrated to YH22162(telmisartan 80mg/amlodipine 5mg/chlorthalidone 25mg) for the remaining 6weeks
Arm Title
telmisartan/amlodipine
Arm Type
Active Comparator
Arm Description
Twynsta(telmisartan 40/amlodipine 5mg) for the first 2 weeks, then force titrated to Twynsta(telmisartan 80mg/amlodipine 5mg) for the remaining 6weeks
Intervention Type
Drug
Intervention Name(s)
telmisartan/amlodipine 40/5mg
Other Intervention Name(s)
Twynsta 40/5 mg
Intervention Type
Drug
Intervention Name(s)
YH22162 40/5/12.5 mg
Other Intervention Name(s)
telmisartan/amlodipine/chlorthalidone 40/5/12.5 mg
Intervention Type
Drug
Intervention Name(s)
telmisartan/amlodipine 80/5mg
Other Intervention Name(s)
Twynsta 80/5 mg
Intervention Type
Drug
Intervention Name(s)
YH22162 80/5/25 mg
Other Intervention Name(s)
telmisartan/amlodipine/chlorthalidone 80/5/25 mg
Intervention Type
Drug
Intervention Name(s)
telmisartan/amlodipine 40/5mg placebo
Other Intervention Name(s)
Twynsta 40/5 mg placebo
Intervention Type
Drug
Intervention Name(s)
YH22162 40/5/12.5 mg placebo
Other Intervention Name(s)
telmisartan/amlodipine/chlorthalidone 40/5/12.5 mg placebo
Intervention Type
Drug
Intervention Name(s)
telmisartan/amlodipine 80/5mg placebo
Other Intervention Name(s)
Twynsta 80/5 mg
Intervention Type
Drug
Intervention Name(s)
YH22162 80/5/25 mg placebo
Other Intervention Name(s)
telmisartan/amlodipine/chlorthalidone 80/5/25 mg placebo
Primary Outcome Measure Information:
Title
Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8
Time Frame
baseline and week 8
Secondary Outcome Measure Information:
Title
Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 2
Time Frame
baseline and week 2
Title
Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 4
Time Frame
baseline and week 4
Title
Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSSBP) at Week 2
Time Frame
baseline and week 2
Title
Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSSBP) at Week 4
Time Frame
baseline and week 4
Title
Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSSBP) at Week 8
Time Frame
baseline and week 8
Title
Patients Achieving Blood Pressure Control at Week 2
Description
Mean sitting blood pressure(MSBP) < 140/90 mmHg
Time Frame
baseline and week 2
Title
Patients Achieving Blood Pressure Control at Week 4
Description
Mean sitting blood pressure(MSBP) < 140/90 mmHg
Time Frame
baseline and week 4
Title
Patients Achieving Blood Pressure Control at Week 8
Description
Mean sitting blood pressure(MSBP) < 140/90 mmHg
Time Frame
baseline and week 8
Title
Reduction From Baseline in Mean Sitting Blood Pressure (MSBP) at Week 2
Description
reduction of MSSBP>= 20 mmHg and reduction of MSSBP>= 10 mmHg
Time Frame
baseline and week 2
Title
Reduction From Baseline in Mean Sitting Blood Pressure (MSBP) at Week 4
Description
reduction of MSSBP>= 20 mmHg and reduction of MSSBP>= 10 mmHg
Time Frame
baseline and week 4
Title
Reduction From Baseline in Mean Sitting Blood Pressure (MSBP) at Week 8
Description
reduction of MSSBP>= 20 mmHg and reduction of MSSBP>= 10 mmHg
Time Frame
baseline and week 8
10. Eligibility
Sex
All
Minimum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Signed Informed Consent
Men and women ≥ 19 years of age
Essential hypertensive patients
If already taking antihypertensive drugs, mean sitting systolic blood pressure (MSSBP) must be 140 mmHg ≤ MSSBP < 200 mmHg
If not taking any antihypertensive drugs at least 4 weeks, mean sitting systolic blood pressure (MSSBP) must be 160 mmHg ≤ MSSBP < 200 mmHg
Exclusion Criteria:
Patients with known or suspected secondary hypertension
Other exclusions applied
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hyunhee Na, MD
Organizational Affiliation
Yuhan Corporation
Official's Role
Study Director
Facility Information:
Facility Name
Yuhan
City
Seoul
Country
Korea, Republic of
12. IPD Sharing Statement
Learn more about this trial
Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment
We'll reach out to this number within 24 hrs